Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fennec Pharmaceuticals ( (TSE:FRX) ) just unveiled an update.
Fennec Pharmaceuticals reported a record-breaking third quarter in 2025, with net product sales reaching $12.5 million, marking a 79% year-over-year growth. The company achieved its first profitable quarter from operations, reflecting the success of its strategic initiatives to strengthen its commercial organization and expand PEDMARK® adoption. Preliminary results from a clinical trial in Japan are expected in the fourth quarter, which could lead to further market expansion and partnerships.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on TSE:FRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:FRX is a Neutral.
Fennec Pharmaceuticals shows strong revenue growth and improved cash flow, key for its industry. However, profitability issues and a weak balance sheet weigh down the score. Technical indicators and valuation reflect mixed signals, while positive earnings call sentiments provide some optimism. Addressing financial challenges will be crucial for future performance.
To see Spark’s full report on TSE:FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for oncology care. Their primary product, PEDMARK®, is aimed at reshaping the standard of care for patients undergoing cisplatin-based treatment.
Average Trading Volume: 1,137
Technical Sentiment Signal: Buy
Current Market Cap: C$305.6M
Learn more about FRX stock on TipRanks’ Stock Analysis page.